Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase clinical data.

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth strategies offset patent expiries.

The first half of 2025 has been topsy-turvy for Bristol Myers BMY. Shares of this biotech giant have lost 16.3% year to date compared with the industry ’s decline of 2.7%. The stock has also ...

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

BioNTech SE (NASDAQ:BNTX) is one of the 13 Best German Stocks to Invest in Now. It is a clinical-stage biotechnology company focused on immunotherapies to treat cancer and other serious diseases ...

In June 2025, BioNTech and Bristol Myers Squibb agreed on the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types.

Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types.

Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

Singer Youngtak will release a duet song with singer Kim Yeonja on the 22nd. The agency, Abyss Company, revealed the concept poster for Youngtak's new digital single 'Juicy Go (Duet with Kim ...